Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss pill enters early human testing

NCT ID NCT07150962

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests two versions of an experimental tablet called HRS9531 in people who are overweight or obese. The main goals are to compare how the body absorbs each version and to check for side effects. About 168 men aged 18-55 with a BMI between 24 and 35 will participate. This research helps determine which formulation is safer and more effective for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, 230601, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.